Pharmaceutical intermediates market development and trend
Custom Synthesis, Over the years, the pharmaceutical intermediates industry is the focus of the world’s key investment and intense competition. Over the past 20 years, the world pharmaceutical industry has made unprecedented progress, to the end of the 90 ‘s, the world drug market scale has reached about 256 billion U.S. dollars/A, pesticide sales of 23 billion U.S. dollars/a around. In terms of medicine, over the past decade, while biotechnology and gene drugs have been evolving as a rookie, important proprietary medicines are being accepted. The development trend of the world pharmaceutical industry in the future is: High-tech, high demand, high speed, high concentration.
The main features are the following four areas:
(1) New drugs are emerging, and the variety is accelerated. such as quinolone acid antibacterial drugs, over the past 30 years, has been chemically synthesized more than 20,000 compounds and antibacterial screening. 1962-1969 years of successful research and development are: naphthalene acid (nalidixic acid), (oxalinic acid) and pyrrole acid (piromidic acid) and so on. The 1970-1977-year period was replaced by Flumequine and norfloxacin (pipemidic acid). Since 1978, fluoroquinolones have been found to be the third generation of quinolones, such as ciprofloxacin (ciprofloxacin, ciprofloxacin), Lomefloxacin (Norfloxacin, lomefloxacin,ny-198), and Ofloxacin (Norfloxacin, ofloxacin), and so on, and so on. Their antibacterial spectrum is wide and the activity is stronger, the curative effect can be comparable with the third generation or the fourth generation cephalosporins.
(2) The difficulty of new drug creation is more and more, management Department of Drug efficacy and safety requirements are increasing, so that the investment in research and development increased dramatically. At the same time, new drug research and development is long-term, continuous, and has a great risk. To adapt to competition in the High-tech field, it will cost huge sums of money. In economically developed countries, research and development costs accounted for a percentage of turnover (c/a≈6.3%,c/b≈17.7%) exceeding the turnover margin (d/a≈5.2%). A-total turnover, B-pharmaceutical sales, C-research development fee, D total profit amount
(3) as a high-tech industry, the pharmaceutical industry needs a high level of knowledge. Pharmaceutical industry companies in various countries are constantly strengthening their research team’s strength. For example, the United States pharmaceutical companies accounted for 15% of the staff, including Ph. D. and master’s degree accounted for 26.7% of scientific research personnel.
(4) Large-scale enterprises increased by mergers, pharmaceutical enterprises in developed countries to expand their economic strength and develop research capabilities to occupy the market, and strive to enter the best size. In France, for example, there were 1960 pharmaceutical companies in 1950, 880 in 1970, 392 in 1980, 1989 down to 358, and 1990 years of mergers in the 10 months of Japanese pharmaceutical companies, In the year 1979-1989 10, there were only 10 in total. They all take the scientific research, the production (including the raw material medicine and the preparation), sells the Trinity the mode of operation and the scale production. They also focus on the future, for the hope to become a large variety of drugs, such as naproxen piperazine acid (Piproxen), Ranitidine (ranitidine), etc., in its patent protection period will be full before the competition to find collaborators, the development of new technology routes and new production technology, the development of production, reduce costs, expand sales, In order to be more conducive to international competitionhttp://www.haihengpharma.com/pharmaceutical-intermediates-market-development-and-trend/News